Document is current

Article History

Received: 17 November 2023

Accepted: 14 March 2024

First Online: 6 April 2024

Declarations

:

: The study was performed in accordance with the Declaration of Helsinki and relevant International Council for Harmonisation, Good Clinical Practice, and Good Pharmacoepidemiological Practice guidelines. As no identifiable protected health information was extracted or accessed for the conduct of this study, ethics approval and informed consent were deemed unnecessary under the Code of Federal Regulations Title 45, Part 46, Section 46.104(d)(4)(ii) (45CFR46.104[d][4][ii]).

: Not applicable.

: H.A.D. was an employee of Sanofi at the time of the study and holds stock in the company. M.A.B. received consulting fees from Sanofi. A.K. is an employee of Sanofi and holds stock in the company. D.P.C. has received funding from clinical trial grants from Genentech and Merck Sharp & Dohme to The Ohio State University; received consulting fees from Bristol Myers Squibb (BMS), BMS KK, Boehringer Ingelheim, Curio Science, Genentech/Roche, GI Therapeutics (Intellisphere), GlaxoSmithKline (GSK), Janssen, Mirati, Novartis, Novacure, OncoCyte, OncoHost, Roche China, and Seattle Genetics; received honoraria from AstraZeneca and BMS; participated in Data Safety Monitoring Boards for European Organisation for Research and Treatment of Cancer (EORTC), AbbVie, and Lilly; and participated in advisory boards for Amgen, Arcus Biosciences, AstraZeneca, Cantargia, Daiichi Sankyo, EMD Serono/Merck, Flame Biosciences, Gritstone Oncology, GSK, Lilly, Regeneron, Sanofi, and Seattle Genetics.